Dr. Kumar on Studies Investigating Venetoclax in Multiple Myeloma

Shaji K. Kumar, MD
Published: Monday, Mar 27, 2017



Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses studies investigating venetoclax (Venclexta) in patients with multiple myelomacl-2 protein.

There are 2 studies looking at the efficacy of venetoclax in patients with multiple myeloma, explains Kumar. One study, which enrolled 66 patients, looked at venetoclax alone, where the maximum dose was determined as well as an overall response rate of 21% in the advanced relapsed patient population. The median progression-free survival for these patients was nearly 12 months.

Additional molecular testing has been done to identify the cohort of patients who are most likely to respond to venetoclax. This identified a group where the response rate was 85%, states Kumar.
 
SELECTED
LANGUAGE


Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses studies investigating venetoclax (Venclexta) in patients with multiple myelomacl-2 protein.

There are 2 studies looking at the efficacy of venetoclax in patients with multiple myeloma, explains Kumar. One study, which enrolled 66 patients, looked at venetoclax alone, where the maximum dose was determined as well as an overall response rate of 21% in the advanced relapsed patient population. The median progression-free survival for these patients was nearly 12 months.

Additional molecular testing has been done to identify the cohort of patients who are most likely to respond to venetoclax. This identified a group where the response rate was 85%, states Kumar.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x